David Meeker starts the next chapter of his long biotech career as chairman of the board
David Meeker may be leaving Sanofi Genzyme after a long run at the big Boston operation, but he’s staying in biotech.
Meeker recently announced his retirement from the Sanofi subsidiary, effective in June, and today he’s taking the chairman’s role at Rhythm, a Boston-based startup that is developing peptide therapies for rare genetic conditions.
Meeker is following a path blazed by former boss Henri Termeer, who followed the $20 billion sale of Genzyme with a high-profile role seeding biotech startups and serving on a variety of boards in the hot life sciences hub.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.